IBA started cyclotron rigging at India's first proton therapy center

IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces the delivery and rigging of the C230 cyclotron at the new Apollo Proton Cancer Center in Chennai, India. 

IBA will equip the center in Chennai with a Proteus®PLUS* multi-room configuration, consisting of two gantry treatment rooms, and one fixed beam treatment room. Each room will be fitted with the most advanced Pencil Beam Scanning and Cone Beam CT (CBCT) technology; as well as the Philips Ambient Experience, an interactive, patient-focused healthcare environment that uses modern technology to create a more comfortable and soothing environment for treatment. 
The Apollo Proton Cancer Center is scheduled to treat its first patient in September 2018. 

Ion Beam Applications has collaborated with Philips India for the Apollo Hospitals Group project. This alliance combines IBA's strengths in proton therapy and Philips expertise in clinical informatics. 

Manoj Sahasrabudhe, Chief Operating Officer, IBA Proton Therapy, commented: "With forty-seven proton therapy systems sold worldwide, and more than half of all installed treatment rooms supplied by IBA, we are the clear leader in proton therapy. We are proud to be working with Apollo Hospitals and Philips India to create a world class proton therapy facility in Chennai; a first for India. This state of the art center will offer cancer patients in India and South-East Asia local access to this advanced cancer treatment." 

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group, added: "As Asia's trusted healthcare provider and a wholly patient-centric organization; we have continuously pioneered the introduction of cutting edge medical advancements to the region, with a view to leave no stone unturned in saving lives. The upcoming state-of-the-art 150-bed Apollo Proton Cancer Center will be on par with the best Oncology centers in the world, enabling us to provide comprehensive cancer care to all our patients. With the first Proton Therapy center in South Asia, this hospital will be accessible to over 3 billion people. Our battle against cancer has spanned over two decades, has witnessed several milestones, and has set new benchmarks in cancer care. Apollo has always been the first to bring the very best in oncology care to India. Now, the Apollo Proton Cancer Center will bring about a transformative shift in cancer care and we look forward to treating the first patient by early September 2018." 
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. 

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). 
More information can be found at: www.iba-worldwide.com 

About Apollo Hospitals 
Apollo Hospitals is widely recognized as the pioneer of private healthcare in India, and was the country's first corporate hospital. The Apollo Hospitals Group, which started as a single 150 bed hospital, today operates 9,550 beds across 64 hospitals. A forerunner in integrated healthcare, Apollo has a robust presence across the healthcare spectrum. The Group has emerged as the foremost integrated healthcare provider in Asia, with mature group companies that specialize in insurance, pharmacy, consultancy, clinics and many such key touch points of the ecosystem. The Apollo Group has touched the lives of over 45 million patients, from 121 countries. 

More information can be found at: https://www.apollohospitals.com/departments/cancer/treatment/radiation-therapy



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types